225 related articles for article (PubMed ID: 17561316)
1. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.
Brisson M; Van de Velde N; De Wals P; Boily MC
Vaccine; 2007 Jul; 25(29):5399-408. PubMed ID: 17561316
[TBL] [Abstract][Full Text] [Related]
2. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
[TBL] [Abstract][Full Text] [Related]
3. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
4. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
5. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
[TBL] [Abstract][Full Text] [Related]
6. Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries.
Termrungruanglert W; Havanond P; Khemapech N; Lertmaharit S; Pongpanich S; Khorprasert C; Taneepanichskul S
Value Health; 2012; 15(1 Suppl):S29-34. PubMed ID: 22265063
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
Demarteau N; Tang CH; Chen HC; Chen CJ; Van Kriekinge G
Value Health; 2012; 15(5):622-31. PubMed ID: 22867770
[TBL] [Abstract][Full Text] [Related]
8. Health and economic implications of HPV vaccination in the United States.
Kim JJ; Goldie SJ
N Engl J Med; 2008 Aug; 359(8):821-32. PubMed ID: 18716299
[TBL] [Abstract][Full Text] [Related]
9. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
[TBL] [Abstract][Full Text] [Related]
10. Age-based programs for vaccination against HPV.
Elbasha EH; Dasbach EJ; Insinga RP; Haupt RM; Barr E
Value Health; 2009; 12(5):697-707. PubMed ID: 19490561
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
Diaz M; de Sanjose S; Ortendahl J; O'Shea M; Goldie SJ; Bosch FX; Kim JJ
Eur J Cancer; 2010 Nov; 46(16):2973-85. PubMed ID: 20638840
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
Lee VJ; Tay SK; Teoh YL; Tok MY
BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
[TBL] [Abstract][Full Text] [Related]
13. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
[TBL] [Abstract][Full Text] [Related]
14. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.
Dasbach EJ; Insinga RP; Elbasha EH
BJOG; 2008 Jul; 115(8):947-56. PubMed ID: 18503574
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
[TBL] [Abstract][Full Text] [Related]
16. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.
Anonychuk AM; Bauch CT; Merid MF; Van Kriekinge G; Demarteau N
BMC Public Health; 2009 Oct; 9():401. PubMed ID: 19878578
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
Annemans L; Rémy V; Oyee J; Largeron N
Pharmacoeconomics; 2009; 27(3):231-45. PubMed ID: 19354343
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of human papillomavirus vaccination in the United Kingdom.
Jit M; Choi YH; Edmunds WJ
BMJ; 2008 Jul; 337():a769. PubMed ID: 18640957
[TBL] [Abstract][Full Text] [Related]
20. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
